Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Total Non-Current Liabilities (2019 - 2021)

Historic Total Non-Current Liabilities for Keros Therapeutics (KROS) over the last 3 years, with Q4 2021 value amounting to $12.1 million.

  • Keros Therapeutics' Total Non-Current Liabilities rose 5766.32% to $12.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was $12.1 million, marking a year-over-year increase of 5766.32%. This contributed to the annual value of $12.1 million for FY2021, which is 5766.32% up from last year.
  • As of Q4 2021, Keros Therapeutics' Total Non-Current Liabilities stood at $12.1 million, which was up 5766.32% from $11.5 million recorded in Q3 2021.
  • Keros Therapeutics' 5-year Total Non-Current Liabilities high stood at $12.1 million for Q4 2021, and its period low was $7.4 million during Q3 2020.
  • Its 3-year average for Total Non-Current Liabilities is $9.4 million, with a median of $9.3 million in 2021.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first crashed by 2592.59% in 2020, then skyrocketed by 5766.32% in 2021.
  • Quarter analysis of 3 years shows Keros Therapeutics' Total Non-Current Liabilities stood at $10.3 million in 2019, then dropped by 25.93% to $7.7 million in 2020, then soared by 57.66% to $12.1 million in 2021.
  • Its last three reported values are $12.1 million in Q4 2021, $11.5 million for Q3 2021, and $7.8 million during Q2 2021.